Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical Commentary: The Challenge of Timing Antiviral Therapy

Clinical Commentary: The Challenge of Timing Antiviral Therapy Clinical Commentary The Challenge of Timing Antiviral Therapy pressing the presence of HIV in the cerebrospinal fluid. Thus in KS patients who may not require specific therapy for lecan By Michaels. Gottlieb, M.D. and Sheila Hutman zidovudine (formerly AZT; Retrovir) was approved by the FDA in 1987, the indications referred to a narrow category of patients, namely adults with symptomatic HIV infection (AIDS and advanced ARC) who had prior PCP or an absolute helper T cell (T4, CD,) count of less than 200 per mm2. In the light of cumulative experience and data from two trials on early stage HIV disease conducted by the NIH AIDS Clinical Trial Groups, the original indications are far too narrow. In the two years since zidovudine was approved, new information supporting modification of the original package insert has gradually accumulated. The 1986 placebo-controlled trial and subsequent experience has proven that patient survival and quality of life are enhanced when zidovudine is started within weeks of an AIDS-defining episode of PCP. Although few studies have specifically analyzed the effect of zidovudine begun after sentinel opportunistic infections other than PCP, the experience of most AIDS clinicians supports the conclusion that the effects on survival http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AIDS Patient Care Mary Ann Liebert

Clinical Commentary: The Challenge of Timing Antiviral Therapy

AIDS Patient Care , Volume 3 (6) – Dec 1, 1989

Clinical Commentary: The Challenge of Timing Antiviral Therapy

AIDS Patient Care , Volume 3 (6) – Dec 1, 1989

Abstract

Clinical Commentary The Challenge of Timing Antiviral Therapy pressing the presence of HIV in the cerebrospinal fluid. Thus in KS patients who may not require specific therapy for lecan By Michaels. Gottlieb, M.D. and Sheila Hutman zidovudine (formerly AZT; Retrovir) was approved by the FDA in 1987, the indications referred to a narrow category of patients, namely adults with symptomatic HIV infection (AIDS and advanced ARC) who had prior PCP or an absolute helper T cell (T4, CD,) count of less than 200 per mm2. In the light of cumulative experience and data from two trials on early stage HIV disease conducted by the NIH AIDS Clinical Trial Groups, the original indications are far too narrow. In the two years since zidovudine was approved, new information supporting modification of the original package insert has gradually accumulated. The 1986 placebo-controlled trial and subsequent experience has proven that patient survival and quality of life are enhanced when zidovudine is started within weeks of an AIDS-defining episode of PCP. Although few studies have specifically analyzed the effect of zidovudine begun after sentinel opportunistic infections other than PCP, the experience of most AIDS clinicians supports the conclusion that the effects on survival

Loading next page...
 
/lp/mary-ann-liebert/clinical-commentary-the-challenge-of-timing-antiviral-therapy-PCpFPTA5WO
Publisher
Mary Ann Liebert
Copyright
Copyright 1989 Mary Ann Liebert, Inc.
ISSN
0893-5068
eISSN
1557-7449
DOI
10.1089/apc.1989.3.5
Publisher site
See Article on Publisher Site

Abstract

Clinical Commentary The Challenge of Timing Antiviral Therapy pressing the presence of HIV in the cerebrospinal fluid. Thus in KS patients who may not require specific therapy for lecan By Michaels. Gottlieb, M.D. and Sheila Hutman zidovudine (formerly AZT; Retrovir) was approved by the FDA in 1987, the indications referred to a narrow category of patients, namely adults with symptomatic HIV infection (AIDS and advanced ARC) who had prior PCP or an absolute helper T cell (T4, CD,) count of less than 200 per mm2. In the light of cumulative experience and data from two trials on early stage HIV disease conducted by the NIH AIDS Clinical Trial Groups, the original indications are far too narrow. In the two years since zidovudine was approved, new information supporting modification of the original package insert has gradually accumulated. The 1986 placebo-controlled trial and subsequent experience has proven that patient survival and quality of life are enhanced when zidovudine is started within weeks of an AIDS-defining episode of PCP. Although few studies have specifically analyzed the effect of zidovudine begun after sentinel opportunistic infections other than PCP, the experience of most AIDS clinicians supports the conclusion that the effects on survival

Journal

AIDS Patient CareMary Ann Liebert

Published: Dec 1, 1989

There are no references for this article.